Pancreatic Cancer Research

GrantZIANCI Division of Basic Sciences (intramural)

PCNA as an oncogenic drug target

Activity
ZIA
Institute
NCI Division of Basic Sciences (intramural)
Fiscal years counted
2024
Amount counted
$200,189

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Abstract public domain (NIH RePORTER)

In this project we are using structure-based drug design to target proliferating cell nuclear antigen, PCNA, a protein that plays an essential role in DNA replication and repair. PCNA has been found to be a marker for poor prognosis of cancer patients in different cancers, such as pancreatic cancer and breast cancer. There are a few PCNA inhibitors already in clinical trials. We are structural biology techniques to determine the structure of PCNA and design novel inhibitors. We are also using a novel compound screening approach in collaboration with the Mackey lab (Virginia Tech), where we can test our compounds in a cellular environment which obtaining clear data of their efficacy in penetrating cells and inhibiting PCNA.